Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- DOCUMENT AND ENTITY INFORMATION
Financial Statements
Notes to Financial Statements
Accounting Policies
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)

v3.10.0.1

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)	1 Months Ended					12 Months Ended
SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)	Oct. 31, 2018 USD ($)	Feb. 28, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2018 USD ($) item	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)
Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable						$ 369,900,000
BerGenBio A S Worldwide License Agreement
Collaborations
Revenue recognized								$ 3,700,000
Specified Development Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable						58,000,000
Specified Regulatory Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable						220,600,000
Specified Product Launch Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable						91,300,000
Kissei
Collaborations
Upfront payment received	$ 33,000,000
Contingent payments	$ 147,000,000
Deferred revenue related to upfront payment						2,400,000
Revenue recognized						$ 30,600,000
Number of unsatisfied performance obligations \| item						2
BMS
Collaborations
Upfront payment received					$ 30,000,000
Contingent payments								309,000,000
Deferred revenue related to upfront payment									$ 30,000,000
Revenue recognized			$ 3,000,000					13,400,000
BMS \| Research Activities
Collaborations
Revenue recognized								$ 290,000
BerGenBio
Collaborations
Upfront payment received				$ 1,700,000
Collaborative payment received		$ 3,300,000
Revenue recognized							$ 3,300,000
Payment received from exercise of option rights				$ 2,000,000

- Definition

Represents the amount of deferred revenue as of balance sheet date related to upfront payment under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementDeferredRevenueRelatedToUpfrontPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the maximum amount of pre-specified contingent payments receivable under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents payments received from exercise of option rights.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementOptionRightsExercised
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of collaboration payment received during the period.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementPaymentsReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the revenue recognized during the period under the terms of sponsored research and license agreements.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementRevenueRecognized
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementUpfrontFeeReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents additional contingent payments by entities.

+ References

No definition available.

+ Details

Name:	rigl_ContingentPaymentsUnderAgreement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of unsatisfied performance obligations.

+ References

No definition available.

+ Details

Name:	rigl_NumberOfUnsatisfiedPerformanceObligations
Namespace Prefix:	rigl_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rigl_BerGenBioASWorldwideLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_BristolMyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_ResearchActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_BerGenBioASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: